ArticleFrontiers in oncology2025
The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Total-body positron emission tomography/computed tomography (PET/CT) using uEXPLORER scanners demonstrates superior imaging capabilities for assessing programmed death ligand 1 (PD-L1) expression heterogeneity between primary tumors (PTs) and metastatic tumors (MTs) in advanced nonsmall cell lung cancer (NSCLC). Methods: This retrospective study of 99 treatment-naïve NSCLC patients revealed that metabolic parameters (SUVmax, SUR-L, and SUR-BP) derived from biopsy-correlated PET/CT sites significantly predicted high PD-L1 expression (TC ≥ 50% or IC ≥ 10% by IHC). Results: SUR-L exhibited the highest diagnostic accuracy (AUC = 0.758, Discussion: Our findings establish SUR-BP as a novel non-invasive biomarker for immunotherapy prognosis in NSCLC, addressing spatial heterogeneity challenges in PD-L1 assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.